On April 29, 2015 GemVax reported that its pancreatic cancer immunity drug, Liabax (codename GV1001), received final marketing approval from the Ministry of Food and Drug Safety from Samsung Pharmaceutical (Press release, Karmanos Cancer Institute, AUG 14, 2020, View Source [SID1234563669]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In September last year, Liabax was approved for the 21st new drug as an anticancer drug for pancreatic cancer from the Ministry of Food and Drug Safety. As a result, the world’s first pancreatic cancer immune anticancer drug was first released in Korea, and new treatment opportunities were created for Korean pancreatic cancer patients.
Ria Bax weeks ‘ destroy cancer cells by maximizing the autoimmune pancreatic cancer patients , a new concept anticancer drugs to prolong the survival of existing chemotherapeutic agents when administered in combination with a cancer patient . Liabax has proven its safety and efficacy by conducting more than 10 clinical trials in 10 European regions including the UK and Norway, as well as Australia and the United States, which could be a breakthrough alternative to the treatment of pancreatic cancer with a low survival rate of 8% . It is expected .
Leah is a gem backstage backstage with Samsung constraints are expected to rush to the hospital full distribution procedures for careful prescribing , revenue this year, three are expected to be in earnest quarter .
In recent years, the development of immunological drugs in anticancer treatment is becoming the mainstream worldwide . Experts predict that immunotherapy offers the possibility of chronic treatment in chemotherapy , and pharmaceutical companies are also taking the development of anticancer drugs using the immune system as an important task .
Geumbeon attention as Patria backstage backstage GEM domestic market was the first to naedinge the first step in cancer immunotherapy market , Liao backstage CAUTION expanded indications is of course also enter motivation accelerate global expansion .
Gem gimsangjae Diamondbacks CEO " Ria Bax is expected to be helpful for domestic patients suffering from pancreatic cancer as the primary market very pleased ." He said , " Ria Bax national attention as one to achieve the first objective of market , the next step Ria Bax care abroad, even accelerating , in addition to be able to perform well in overseas areas of the existing product lineup of Samsung Pharmaceuticals I will try ." Said.